A robust second quarter, approval of HIV drug Truvada (emtricitabine/tenofovir disoproxil fumarate) for prophylactic use and competitor setbacks that could add to its lead in the race for an all-oral hepatitis C virus regimen all contributed to an impressive summer for Gilead Sciences Inc.